Mushroom cap with stem cut off

LSD and Psilocybin Therapy research was once widespread across the United States. Much of it stopped, when LSD, promoted by anti-establishment iconoclasts like Timothy Leary, provoked a powerful reaction from the U.S. Government and draconian laws banning psychedelics, with no distinction made between “party drugs” and legitimate therapeutic research.

MDMA is another drug that is now being tested in clinical environments again.

Today there is a grand comeback underway involving psilocybin therapy – psilocybin taken in controlled, therapeutic settings. Across the world, it is being evaluated for its ability to address treatment-resistant depression and end-of-life anxiety in terminal patients, as well as chronic ailments like addiction and acute migraine headaches.

It is unclear whether LSD will be studied clinically or will simply reclaim its party drug crown.

The “don’t throw out the baby with the bathwater” message has finally been heard after many decades. Psilocybin has the possibility of changing the world, with legalization and adaptation by the medical field clearly on the horizon.

Read Luminosity’s article on the psilocybin therapy movement and cultural shift.

Artwork credit: Psilocybin Therapy Training For Depression | Psych by psychedelicsomatic

Leave a Reply

Your email address will not be published. Required fields are marked *